Congenital myasthenia with congenital endplate acetylcholinesterase deficiency (Q104865)

From determinar.ia.br - Determine suas informações
Revision as of 10:43, 17 August 2026 by Determinaradmin (talk | contribs) (‎Changed label, description and/or aliases in pt-br, en)
Autosomal recessive endplate Acetylcholinesterase (AChE) deficiency, a Congenital myasthenic syndrome (CMS) subtype caused by Collagenic tail of endplate acetylcholinesterase (ColQ) mutations with onset from birth to 2 years, presents with hypotonia and proximal muscle weakness or delayed motor milestones. Extraocular muscle weakness and ptosis are always present, bulbar symptoms in half of the patients, respiratory crises in one-third. Occasionally delayed pupillary light reflex. The course varies from progressive severe weakness in the neonate to less severe symptoms during childhood with minimal progression. More than 80% is ambulant on follow-up and has no respiratory trouble despite crises. The patients respond to ephedrine and salbutamol, not to AChE inhibitors.
Language Label Description Also known as
default for all languages
ID_1394279590
    English
    Congenital myasthenia with congenital endplate acetylcholinesterase deficiency
    Autosomal recessive endplate Acetylcholinesterase (AChE) deficiency, a Congenital myasthenic syndrome (CMS) subtype caused by Collagenic tail of endplate acetylcholinesterase (ColQ) mutations with onset from birth to 2 years, presents with hypotonia and proximal muscle weakness or delayed motor milestones. Extraocular muscle weakness and ptosis are always present, bulbar symptoms in half of the patients, respiratory crises in one-third. Occasionally delayed pupillary light reflex. The course varies from progressive severe weakness in the neonate to less severe symptoms during childhood with minimal progression. More than 80% is ambulant on follow-up and has no respiratory trouble despite crises. The patients respond to ephedrine and salbutamol, not to AChE inhibitors.

      Statements